|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
1994-12-12
|
|
pubmed:abstractText |
We analysed human anti-mouse antibodies (HAMA) in 12 patients (six with multiple myeloma (MM) and six with metastatic renal cell carcinoma (MRCC) who were treated with B-E8, an IgG1 MoAb against IL-6. Efficiency of the treatment was evidenced by the drop in the serum levels of C-reactive protein (CRP), the in vivo production of which is under the control of IL-6. Three patients with MM and the six patients with MRCC became immunized to the injected MoAb. HAMA appeared between days 7 and 15 after the beginning of the treatment. The nine patients made IgG antibodies; four also made IgM. All immunized patients made anti-idiotype antibodies specific to B-E8. Two of them also developed HAMA directed to murine IgG1 isotype; in these two patients B-E8 MoAb cleared rapidly from the circulation with loss of treatment efficiency. In the patients who developed only anti-idiotype antibodies, serum levels of B-E8 remained unchanged and CRP production remained inhibited, indicating that treatment remained efficient in the presence of HAMA. Circulating B-E8 MoAbs were still able to bind to IL-6 and to inhibit IL-6-dependent proliferation despite the presence of anti-idiotypic HAMA. Therefore, in contrast to HAMA produced against MoAb directed against cellular targets, HAMA against anti-IL-6 MoAb idiotopes led neither to clearance nor to functional inactivation of the injected MoAb. This was further shown by resuming the B-E8 treatment with success in a patient who still had anti-idiotypic HAMA.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/7955540-13034922,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7955540-1425909,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7955540-1490360,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7955540-1498329,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7955540-1715218,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7955540-1720501,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7955540-2025306,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7955540-2104241,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7955540-2104281,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7955540-2151769,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7955540-2624330,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7955540-2787758,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7955540-3086976,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7955540-3258060,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7955540-3487589,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7955540-3874237,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7955540-6759145,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7955540-6786392,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7955540-8474061
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0009-9104
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
98
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
323-9
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:7955540-Adult,
pubmed-meshheading:7955540-Aged,
pubmed-meshheading:7955540-Animals,
pubmed-meshheading:7955540-Antibodies, Heterophile,
pubmed-meshheading:7955540-Antibodies, Monoclonal,
pubmed-meshheading:7955540-Carcinoma, Renal Cell,
pubmed-meshheading:7955540-Female,
pubmed-meshheading:7955540-Humans,
pubmed-meshheading:7955540-Interleukin-6,
pubmed-meshheading:7955540-Male,
pubmed-meshheading:7955540-Mice,
pubmed-meshheading:7955540-Middle Aged,
pubmed-meshheading:7955540-Multiple Myeloma
|
|
pubmed:year |
1994
|
|
pubmed:articleTitle |
Human anti-mouse antibody response to the injection of murine monoclonal antibodies against IL-6.
|
|
pubmed:affiliation |
INSERM U291, Montpellier, France.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
